AMA CPT® Assistant - 2018 Issue 8 (August)
New Multianalyte Assays with Algorithmic Analyses Codes for Prostate Oncology (August 2018)
August 2018 page 8 New Multianalyte Assays with Algorithmic Analyses Codes for Prostate Oncology Two new Category I codes (81541, 81551) were added to the Pathology and Laboratory/Multianalyte Assays with Algorithmic Analyses (MAAA) subsection of the Current Procedural Terminology (CPT®) 2018 code set. These codes describe the molecular diagnostic analysis of genes expressed in patients with early stage prostate cancer to calculate a mortality risk score (81541) and the early detection of prostate cancer, while also addressing previously false negative biopsy concerns (81551). Both codes were added to the Category I MAAAs in Appendix O, which also includes...
Subscribe or sign in to view the full article.
Article Overview
This August 2018 CPT Assistant article covers the addition of two prostate oncology multianalyte assay with algorithmic analyses (MAAA) codes to the CPT 2018 code set. It provides a high-level overview of how these codes fit into the pathology and laboratory MAAA subsection, the role of Appendix O, and the types of prostate cancer molecular testing discussed. The article is most relevant to coders, billing staff, laboratory professionals, and urology-related practices that report molecular diagnostic services.
Why This Topic Matters
MAAA reporting can depend on specific assay characteristics, appendices, and proprietary test listings, so understanding the scope of the article helps readers identify whether they need the full guidance for compliant reporting of prostate oncology molecular tests.
Article Sections
-
August 2018 page 8
Introductory publication context for the CPT Assistant article and its prostate oncology focus.
-
New Multianalyte Assays with Algorithmic Analyses
Overview of the newly added prostate oncology MAAA codes, their placement in the CPT code set, and the role of Appendix O in reporting.
-
Clinical Example and Description of Service
Illustrative prostate oncology scenarios paired with general service descriptions for the two assays discussed in the article.
What You Will Learn
- How the article frames prostate oncology MAAA reporting within CPT
- What broad categories of molecular prostate testing are discussed
- How Appendix O is referenced in relation to proprietary assays
- What kinds of clinical scenarios are illustrated for the new prostate oncology assay codes
Who Should Read This
- Medical coders
- Coding compliance staff
- Pathology and laboratory professionals
- Urology practice staff
- Billing and reimbursement personnel
Codes Discussed
Subscribe or sign in to view the full article.


Quick, Current, Complete - www.findacode.com